EnWave Signs Master Service Agreement and First Work Order with BioTechnique LLC
MWN-AI** Summary
EnWave Corporation, a leader in vacuum microwave dehydration technology, announced on March 27, 2025, the signing of a master service agreement with BioTechnique LLC, an American pharmaceutical contract manufacturer. This strategic partnership aims to evaluate EnWave’s Radiant Energy Vacuum (REV™) technology as a potential alternative to traditional lyophilization in the biopharmaceutical sector.
Under the terms of the agreement, BioTechnique will conduct paid testing of various liquid products dried in vials utilizing pilot-scale REV™ machinery at EnWave's Innovation Center in Delta, British Columbia. Should the tests prove successful, BioTechnique may opt to purchase its own REV™ equipment to streamline service delivery for prominent pharmaceutical clients.
BioTechnique specializes in providing contract research, development, and manufacturing services for therapeutic and potent sterile injectables, including both liquid and lyophilized formats. The company is equipped to manage clinical and commercial production batches and offers extensive project management and client services, encompassing formulation, compounding, quality control testing, temperature-controlled storage, and fill-finish processes.
EnWave, headquartered in Delta, BC, has established a comprehensive intellectual property portfolio that enhances its REV™ technology, making it a transformative and efficient drying solution for food, cannabis, and pharmaceutical industries. With over fifty global partners, EnWave claims its technology significantly improves drying speed, product quality, and cost-effectiveness compared to conventional methods.
This collaboration with BioTechnique underscores EnWave's commitment to advancing its innovative dehydration technology and expanding its influence in the biopharmaceutical market. The strategic pairing is expected to benefit both entities, propelling advancements in product quality and manufacturing efficiency in the healthcare domain.
MWN-AI** Analysis
EnWave Corporation's recent signing of a master service agreement (the "Agreement") with BioTechnique LLC represents a significant strategic move that investors should closely monitor. This collaboration focuses on EnWave's innovative Radiant Energy Vacuum (“REV™”) dehydration technology, positioning it as a potential alternative to traditional lyophilization in the biopharmaceutical sector.
This partnership is critical for EnWave as it highlights the growing demand for more efficient drying technologies in life sciences. By enabling BioTechnique to evaluate REV™ through paid testing of various liquid products, EnWave not only showcases the versatility of its technology but also opens the door for potentially lucrative licensing agreements should BioTechnique decide to procure its own REV™ machinery in the future.
Given BioTechnique's standing as a reputable contract manufacturing service provider, the successful integration of REV™ could enhance the quality and efficiency of their drug production processes. This, in turn, could attract a broader client base within the pharmaceutical industry, significantly bolstering EnWave's revenue potential through royalties and equipment sales.
Investors should take note of the broader implications of this agreement. EnWave's established presence with over fifty partners globally indicates a solid foundation for scaling operations. If the collaboration with BioTechnique proves successful, it could catalyze a wave of similar partnerships, amplifying EnWave’s market penetration in both the biopharmaceutical and food industries.
However, investors should remain cautious and consider the risks associated with new partnerships and the reliance on third parties for successful outcomes. The company's forward-looking statements suggest that while the potential is substantial, actual results depend on various external factors which may not align with expectations. Therefore, while EnWave’s prospects appear promising, due diligence and a balanced view of the risks involved are essential for any investment decision.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
VANCOUVER, British Columbia, March 27, 2025 (GLOBE NEWSWIRE) -- EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") announced today that it has signed a master service agreement (the “Agreement”) with BioTechnique, an American pharmaceutical contract manufacturing service provider. This Agreement outlines the terms for the continued evaluation by BioTechnique of EnWave’s Radiant Energy Vacuum (“REV™”) dehydration technology as a suitable replacement for lyophilization in the biopharmaceutical industry.
The first anticipated collaboration will include paid testing of several liquid products to be dried in vials using pilot-scale REV™ machinery at EnWave’s Innovation Center in Delta, British Columbia. If deemed successful, BioTechnique may decide to acquire their own REV™ equipment for service provision directly for their client base of leading pharmaceutical companies.
About BioTechnique LLC
BioTechnique is an American pharmaceutical contract research, development and manufacturing facility filling the need for therapeutic and highly potent sterile injectable products – both liquid and lyophilized. BioTechnique ® ’s filling lines can handle both clinical and commercial batches.
BioTechnique’s project management and client services staff work closely with their clients to provide services for formulation and compounding, QC testing, temperature-controlled storage, fill-finish, and lyophilization for a wide variety of injectable products.
For more information about BioTechnique, please visit www.biotechnique.com .
About EnWave
EnWave is a global leader in the innovation and application of vacuum microwave dehydration. From its headquarters in Delta, BC, EnWave has developed a robust intellectual property portfolio, perfected its Radiant Energy Vacuum (REV™) technology, and transformed an innovative idea into a proven, consistent, and scalable drying solution for the food, pharmaceutical and cannabis industries that vastly outperforms traditional drying methods in efficiency, capacity, product quality, and cost.
With more than fifty partners spanning twenty-four countries and five continents, EnWave’s licensed partners are creating profitable, never-before-seen snacks and ingredients, improving the quality and consistency of their existing offerings, running leaner and getting to market faster with the company’s patented technology, licensed machinery, and expert guidance.
EnWave’s strategy is to sign royalty-bearing commercial licenses with food producers who want to dry better, faster and more economical than freeze drying, rack drying and air drying, and enjoy the following benefits of producing exciting new products, reaching optimal moisture levels up to seven times faster, and improve product taste, texture, color and nutritional value.
Learn more at EnWave.net .
EnWave Corporation
Mr. Brent Charleton, CFA
President and CEO
For further information:
Brent Charleton, CFA, President and CEO at +1 (778) 378-9616
E-mail: bcharleton@enwave.net
Dylan Murray, CPA, CA, CFO at +1 (778) 870-0729
E-mail: dmurray@enwave.net
Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures, and the expected synergies following the closing are forward-looking statements. All third-party claims referred to in this release are not guaranteed to be accurate. All third-party references to market information in this release are not guaranteed to be accurate as the Company did not conduct the original primary research. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FAQ**
How does Enwave Corporation ENW:CC plan to demonstrate the effectiveness of its REV™ technology in comparison to traditional lyophilization methods in the upcoming collaboration with BioTechnique?
What specific advantages does Enwave Corporation ENW:CC expect BioTechnique to gain by adopting its REV™ technology for their biopharmaceutical production processes?
How will the potential acquisition of REV™ equipment by BioTechnique impact the growth strategy and revenue streams for Enwave Corporation ENW:CC in the biopharmaceutical sector?
What are the anticipated challenges faced by Enwave Corporation ENW:CC in scaling its REV™ technology within the competitive biopharmaceutical market, especially in relation to traditional drying methods?
**MWN-AI FAQ is based on asking OpenAI questions about Enwave Corp Canada (OTC: NWVCF).
NASDAQ: NWVCF
NWVCF Trading
6.62% G/L:
$0.2028 Last:
126,675 Volume:
$0.20 Open:
